Gabapentin Capsule
Product Images NDC 31722-149

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 31722-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg (100mg 1000count)

Gabapentin Capsules, USP is a prescription drug manufactured by Ascent Pharmaceuticals for Camber Pharmaceuticals, Inc. Each capsule includes 100 mg of gabapentin, which is used for treating seizures and nerve pain caused by shingles. It is important for the pharmacist to distribute the medication guide to each patient separately. The drug should be stored at Controlled Room Temperature, with excursions permitted between 15 to 30 degree Celsius (59 to 86 degrees Fahrenheit). The dosage and usage information can be found on the package insert. This drug is available in bottles containing 1000 capsules and should be dispensed in a tight, child-resistant container.*

FDA Label Image

100 mg (100mg 100counts)

Gabapentin Capsules, USP is a medication that contains 100mg of Gabapentin per capsule. It comes in a bottle of 100 capsules, Rx only. This medication should be stored at 26°C (77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F), in tightly closed and child-resistant containers. Each patient should be provided with a medication guide from the pharmacist. The dosage and usage instructions can be found in the package insert. Manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY and distributed by Camber Pharmaceuticals, Inc. in Piscataway, NJ.*

FDA Label Image

100 mg (100mg 500count)

This is a description of Gabapentin capsules containing 100mg of Gabapentin,USP. It includes details on how it should be dispensed, stored, and dosed. There is also a Medication Guide that should be provided separately to each patient. The manufacturer is Ascent Pharmaceuticals, Inc. and it is distributed by Camber Pharmaceuticals, Inc.*

FDA Label Image

300 mg (300mg 100count)

Gabapentin is a medication available in the form of capsules that contain 300mg of the active ingredient. It is intended for Rx use only and should be stored at temperatures ranging between 16°C to 30°C. The medication guide should be provided to each patient. The capsules should be dispensed in tightly packed, child-resistant containers. Full prescribing information can be found in the package insert. The medication is manufactured by Ascent Pharmaceuticals, Inc. for Camber Pharmaceuticals, Inc.*

FDA Label Image

300 mg (300mg 500count)

This is a description of a medication called Gabapentin. It comes in the form of capsules with 300mg of the active ingredient per capsule. There are 500 capsules in a container, and the medication should be stored at temperatures between 15° to 30°C (59° to 86°F). The medication guide should be provided to patients by the pharmacist. The medication is manufactured by Ascent Pharmaceuticals, Inc. in Central Isip, NY 11722, and marketed by Camber Pharmaceuticals, Inc. in Piscataway, NJ 08854.*

FDA Label Image

400 mg (400mg 100count)

This is a description of Gabapentin Capsules, manufactured and distributed by Camber Pharmaceuticals. It contains 100 capsules, each with 400 mg of gabapentin, and should be stored at room temperature with excursions permitted between 15 to 30 degrees Celsius. A medication guide should be provided to each patient and the drug must be dispensed in child-resistant containers. Full prescribing information can be found in the package insert. The medicine should be dispensed by a pharmacist. The details of the manufacturer and distributor are also given.*

FDA Label Image

400 mg (400mg 500count)

Gabapentin Capsules, USP is a medication used to treat epileptic seizures and neuropathic pain. The medication is dispensed in a container of 500 capsules, and each capsule contains 400 mg of gabapentin, USP. The medication guide should be provided to each patient. The medication should be stored between 15°C to 30°C (59°F-86°F) and dispensed in a tight, child-resistant container. It is manufactured by Ascent Pharmaceuticals and distributed by Camber Pharmaceuticals, Inc. For more information, refer to the package insert.*

FDA Label Image

Equation (Equ)

This appears to be a formula for calculating the estimated glomerular filtration rate (eGFR) using age, weight, and serum creatinine levels. The formula appears to be modified for female patients by multiplying the result by 0.85. This measure is important for assessing kidney function and determining appropriate treatment for kidney disease.*

FDA Label Image

Fig 1 (Fig 1)

The provided text is a caption for a chart, likely in a medical research study evaluating weekly mean pain scores. It belongs to "Study 1" and shows the observed cases in an "ITT Population."*

FDA Label Image

Fig 2 (Fig 2)

FDA Label Image

Fig 3 (Fig 3)

FDA Label Image

Fig 4 (Fig 4)

This is a figure showing the responder rate of patients receiving Gabapentin as adjunctive therapy in treating partial seizures. The responder rate is expressed as a difference from placebo by dose and study in patients over 12 years of age. Gabapentin daily doses of 300mg, 900mg, and 1800mg are shown on the graph. There is no additional text available describing the results.*

FDA Label Image

Structure (Struct)

FDA Label Image

Table 1 (Tab 1)

This is a table showing the dosage of Gabapentin based on renal function as well as creatinine clearance. The dosages are presented in milligrams per day, and the frequency of administration is shown in terms of BID (twice a day), TID (three times a day), and QD (once a day). Patients on hemodialysis require maintenance doses based on creatinine clearance and an additional supplemental dose administered after each 4 hours of hemodialysis. For patients with creatinine clearance less than 15 mU/min, daily dose is reduced in proportion to creatinine clearance.*

FDA Label Image

Table 2 (Tab 2)

This text reports a table that shows the relative risk, incidence of events, and risk difference by indication for antiepileptic drugs. The indications include epilepsy, psychiatric, and other. The table compares results between placebo patients and those taking the drug from pooled analysis data. The incidence of events was measured per 1,000 patients. The relative risk and incidence of events were higher for psychiatric patients and lower for other patients. Risk difference was measured as the additional drug patients with events per 1,000 patients.*

FDA Label Image

Table 3 (Tab 3)

This is a table showing adverse reactions in pooled placebo-controlled trials in postherpetic neuralgia. The table shows the percentage of individuals who experienced adverse reactions when taking Gabapentin compared to those taking a placebo. The adverse reactions are categorized by body system including body as a whole, digestive system, metabolic and nutritional disorders, nervous system, respiratory system, and special senses. The adverse reactions include asthenia, diarrhea, dizziness, somnolence, blurred vision, and more.*

FDA Label Image

Table 4 (Tab 4)

This is a table showing the percentage of adverse reactions in pooled placebo-controlled add-on trials in epilepsy patients over the age of 12 years who were given Gabapentin. The table includes adverse reactions related to the body as a whole, cardiovascular, digestive, nervous, respiratory, skin and appendages, urogenital, and special senses systems. The adverse reactions include somnolence, dizziness, dyspepsia, and increased weight, among others. Blurred vision (amblyopia) was also reported. Background antiepileptic drug therapy was used in combination with Gabapentin.*

FDA Label Image

Table 5 (Tab 5)

This is a table presenting the adverse reactions of Gabapentin, a drug used as add-on treatment for epilepsy in children aged 3 to 12 years old, during a placebo-controlled trial. The table shows the number of patients experiencing certain side effects with their corresponding percentages, categorized by body system affected. The adverse reactions include viral infection, fever, increased weight, fatigue, nausea and/or vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis, and respiratory infection. The trial included 119 patients who were also receiving other antiepileptic drugs.*

FDA Label Image

Tab 6 (Tab 6)

This is a table showing the duration, dosages, and number of patients in controlled PHN studies involving Gabapentin. The table includes information on 2 studies, including the target dose of Gabapentin, the duration in weeks, the number of patients taking Gabapentin and placebo, and the dosage given in 3 divided doses per day (TID).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.